A Study to Investigate the Efficacy, Safety, and Tolerability of JNJ-42165279 in Adolescent and Adult Participants With Autism Spectrum Disorder
- First Posted Date
- 2018-09-10
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 78
- Registration Number
- NCT03664232
- Locations
- 🇺🇸
BioBehavioral Research of Austin PC, Austin, Texas, United States
🇺🇸Harmonex Neuroscience Research, Dothan, Alabama, United States
🇺🇸Southwest Autism Research and Resource Center, Phoenix, Arizona, United States
A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
- Conditions
- Colitis, Ulcerative
- Interventions
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 214
- Registration Number
- NCT03662542
- Locations
- 🇦🇺
Nepean Hospital, Kingswood, Australia
🇺🇸Precision Research Institute, San Diego, California, United States
🇦🇷Centro Médico Dra. De Salvo, Caba, Argentina
Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Drug: JNJ-53718678Drug: Placebo
- First Posted Date
- 2018-09-04
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 246
- Registration Number
- NCT03656510
- Locations
- 🇺🇸
Madera Family Medical Group, Madera, California, United States
🇺🇸Saltzer Medical Group, Nampa, Idaho, United States
🇺🇸SUNY Upstate Medical University - Upstate Golisano Children's Hospital (GCH), Syracuse, New York, United States
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2018-08-29
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 395
- Registration Number
- NCT03652064
- Locations
- 🇵🇱
Centrum Onkologii Ziemi Lubelskiej im sw Jana z Dukli, Lublin, Poland
🇺🇸Innovative Clinical Research Inc, Cerritos, California, United States
🇺🇸Baptist MD Anderson, Jacksonville, Florida, United States
A Study of Single and Multiple Ascending Doses of JNJ-61393215 in Healthy Participants
- Conditions
- Healthy
- Interventions
- Drug: JNJ-61393215Drug: Placebo
- First Posted Date
- 2018-08-28
- Last Posted Date
- 2019-01-24
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 57
- Registration Number
- NCT03649997
- Locations
- 🇳🇱
PRA Health Sciences, Groningen, Netherlands
A Study of Guselkumab in Participants With Familial Adenomatous Polyposis
- First Posted Date
- 2018-08-28
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 77
- Registration Number
- NCT03649971
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Wexner Medical Center at the Ohio State University, Columbus, Ohio, United States
A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
- Conditions
- Hidradenitis Suppurativa
- Interventions
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 184
- Registration Number
- NCT03628924
- Locations
- 🇺🇸
Great Lakes Clinical Trials, Chicago, Illinois, United States
🇺🇸Clinical Studies Group, Henderson, Nevada, United States
🇺🇸Park Avenue Dermatology, Orange Park, Florida, United States
A Study for Schizophrenia Relapse Prediction
- Conditions
- Schizophrenia
- Interventions
- Drug: Oral Antipsychotics (OAP)
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 333
- Registration Number
- NCT03629951
- Locations
- 🇮🇳
Asha hospital, Hyderabad, India
🇮🇳Mahendru Psychiatric Centre, Kanpur, India
🇮🇳Panchshil Hospital, Ahmedabad, India
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-64264681 in Healthy Male and Female Participants
- Conditions
- Healthy
- Interventions
- Drug: JNJ-64264681Drug: Placebo
- First Posted Date
- 2018-07-31
- Last Posted Date
- 2019-08-22
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 105
- Registration Number
- NCT03607513
- Locations
- 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium
A Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Adults: a Thorough ECG Study Employing Placebo, JNJ-64565111, and a Positive Control (Moxifloxacin)
- Conditions
- Healthy
- Interventions
- Drug: JNJ-64565111Drug: MoxifloxacinDrug: Moxifloxacin-matching PlaceboDrug: JNJ-64565111-matching Placebo
- First Posted Date
- 2018-07-30
- Last Posted Date
- 2020-03-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 188
- Registration Number
- NCT03606057
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States